Does niraparibabiraterone tablets belong to the category of targeted drugs?

Niraparib Abiraterone Tablets (Akeega) combines two targeted anti-cancer drugs with different mechanisms of action - the PARP inhibitor niraparib and the CYP17 inhibitor Abiraterone acetate - in the same treatment regimen for the treatment of castration-resistant prostate cancer (mCRPC). Judging from its pharmacological mechanism of action, this compound combination clearly belongs to the category of targeted drugs and represents the forefront of the development of precision tumor treatment. The essence of targeted drugs is to interfere with the growth, division or metabolic pathways of cancer cells by acting on specific molecular targets, achieving selective killing of tumor cells while relatively reducing damage to normal cells.

Niraparib interferes with the DNA single-strand repair mechanism by selectively inhibitingPARP enzyme, and is especially sensitive to cancer cells with defects in HRR pathways such as BRCA1/2. This mechanism has shown promising efficacy in prostate cancer patients harboring homologous recombination repair deficiency (HRD) mutations. Abiraterone targets the CYP17 enzyme and inhibits androgen synthesis. It is a classic endocrine target drug for prostate cancer treatment. The combined application of these two mechanisms not only blocks the androgen signaling pathway, but also cuts off the ability of tumor cells to repair DNA damage, constituting a double blow.

In addition, the prerequisite for the use of niraparib and abiraterone tablets depends onHRR mutation detection results. This "gene-guided therapy" strategy is closer to the modern concept of individualized and precise tumor treatment. This is in sharp contrast to the "non-selective" mode of action of traditional chemotherapy or hormone therapy. From the aspects of approval path, drug classification, clinical research design, etc., this combination program has been included in the targeted treatment options by mainstream international guidelines.

Therefore, whether from the perspective of pharmacological mechanism, indication specificity, or genetic testing guidance, niraparib and abiraterone tablets clearly belong to the modern targeted drug system and are an important part of the new paradigm of prostate cancer treatment.

Reference materials:https://www.drugs.com/akeega.html